NEW YORK (GenomeWeb News) – Shares of Accelr8 Technology rose 51 percent in Thursday afternoon trade after the firm issued a release saying it had presented results on its rapid tests for identifying multi-resistant organisms at the recent 109th General Meeting of the American Society for Microbiology.
Accelr8 said that it reported results for its rapid test for identifying organisms that produce the new KPC antibiotic-destroying enzyme. "KPC is the first rapidly spreading resistance enzyme to emerge that attacks all members of the largest and most important antibiotic super-family," Accelr8 said in a statement.
The Denver-based firm did not provide further details from the study.
It also said that it reported additional results from a collaborative study with the Denver Health Medical Center on new tests for two additional multi-drug resistant bacteria, Pseudomonas aeruginosa and Acinetobacter baumannii. Accelr8 said that researchers using its BACcel prototypes in three different labs yielded accurate results in less than three hours as compared to the two to three days required for standard culturing tests.
Acceler8 also noted that it had received a new US patent covering its OptiChem technology for hydroxyl functional coatings.
In late Thursday trade on the New York Stock Exchange, shares of Accelr8 were up $1.07 at $3.16.